Remove tag us
article thumbnail

Orchard sets new gene therapy price tag at $4.25M—the steepest of any drug in the US

Fierce Pharma

After scoring an FDA nod Monday for the first gene therapy to treat the rare genetic disease metachromatic leukodystrophy (MLD) in the U.S., Kyowa Kirin and its subsidiary Orchard Therapeutics have | After scoring an FDA nod Monday for the first gene therapy to treat the rare genetic disease metachromatic leukodystrophy in the U.S.,

FDA 284
article thumbnail

Orchard’s MLD gene therapy becomes costliest US medicine

pharmaphorum

Orchard Therapeutics has revealed the US price of Lenmeldy, its gene therapy for rare disease MLD, placing a $4.25m price tag on the one-shot treatment

Medicine 104
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Sanders takes aim at US drug prices of Novo’s Ozempic and Wegovy

Pharmaceutical Technology

A Senate Committee is investigating the “outrageously high” US price tags of the blockbuster diabetes and obesity drugs.

52
article thumbnail

Oligonucleotide synthesis market to reach $16.7 billion by 2027

European Pharmaceutical Review

CSBIO (US). Danaher Corporation (US). Tag Copenhagen A/S (Denmark). Tag Copenhagen A/S (Denmark). Twist Bioscience Corporation (US). Maravai Life Sciences (US). Agilent Technologies, Inc. (US). Alnylam Pharmaceuticals, Inc. (US). ATDBio Ltd. ( Biogen Inc. (US). Biolegio B.V. Netherlands). LGC Limited (UK).

article thumbnail

bluebird bio wins back-to-back landmark FDA approvals for first-in-class gene therapies

Pharmaceutical Technology

Spark Therapeutics’ Luxturna, indicated for inherited retinal disease (IRD), was the first gene therapy to be approved, in 2017, with a price tag of $850,000 for each eye. Prior to bluebird's approvals, there were only two FDA-approved gene therapies for inherited conditions on the market.

FDA 115
article thumbnail

Cost of disease-modifying therapies for multiple sclerosis continues to rise in US

Pharmaceutical Technology

DMTs for MS have a high price tag, particularly in the US. According to GlobalData’s recent Multiple Sclerosis: Seven-Market Drug Forecast and Market Analysis to 2030 – Update report, which identified 19 DMTs marketed for MS in the US, the average annual cost of therapy increased by 9% between 2020 and 2022.

article thumbnail

3 Things Generative AI Can Do for Commercial Pharma Right Now

PM360

While the jury is still out on how far AI will take us, there is little question that large language models (LLMs), or generative AI, offer an impressive amount of promise. If handled properly, LLMs will play an important role in improving data capture and automation, creating efficiencies that will enable us to achieve much more with less.

Pharma 97